Syros Pharmaceuticals, Inc. · OTC:SYRS
Syros Pharmaceuticals — JP Morgan Conference January 2024
18 slides from Syros Pharmaceuticals's conference presentation, Jan 8, 2024
Slide 1: Advancing Novel Treatments for Hematologic Malignancies
Advancing Novel Treatments for Hematologic Malignancies JP Morgan Conference January 2024 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical dev
Slide 3: Advancing our vision to deliver on the value of tamibarotene
Advancing our vision to deliver on the value of tamibarotene Commercial company delivering new standard of care for frontline treatment of hematologic malignancies Advancing tamibarotene as a potential new standard of care for HR-MDS and AML patients with RARA gene overexpression Preparing for produ
Slide 4: Advancing Tamibarotene: Potential to establish new standard of care
Advancing Tamibarotene: Potential to establish new standard of care for the frontline treatment of hematologic malignancies LARGE MARKET OPPORTUNITIES IN FRONTLINE SETTINGS Building a focused infrastructure to support targeted patient populations underserved by existing options MEANINGFUL NEAR-TERM
Slide 5: Multiple near-term value-driving milestones and pre-launch activities underway
Multiple near-term value-driving milestones and pre-launch activities underway Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial Pivotal data from SELECT-MDS-1 Phase 3 trial Initial data from randomized SELECT-AML-1 trial Dec. 2023 Additional data from randomized SELECT-A
Slide 6: Tamibarotene: Compelling profile that addresses large targeted populations
Tamibarotene: Compelling profile that addresses large targeted populations Tamibarotene is a selective and potent RARa agonist1 1McKeown, Cancer Discovery 2017; 2de Botton S., et al. Blood Advances 2022 ~50% of patients with AML are positive for RARA overexpression2 ~30% Normal RARA overexpression w
Slide 7: Growing body of clinical evidence for tamibarotene in HR-MDS and AML
Growing body of clinical evidence for tamibarotene in HR-MDS and AML patients with RARA overexpression supports development strategy 1Data presented at ASH 2017, and Syros Data on File; 2de Botton S., et al. Blood Advances 2022; 3Response includes CR, CRi or CRh; 4Data presented by Syros 06Dec2023 S
Slide 8: Tamibarotene has demonstrated a well-tolerated safety profile
Tamibarotene has demonstrated a well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al. Blood Advances 2022; 4Data presented at ASH 2022; 5Data presented by Syros 06Dec2023 50% CRi 33% CR Data from randomized portion of SE
Slide 9: Significant unmet need in newly diagnosed unfit AML
Significant unmet need in newly diagnosed unfit AML 1 Ferrara F., Clin Lymphoma Myeloma Leuk. 2011; 2DiNardo CD, et al., New England Journal of Medicine, 2020; 3Maiti A., et al., Haematologica, 2021. Acute myeloid leukemia (AML) is a cancer of the blood forming cells in the bone marrow ~50% of the p
Slide 10: SELECT-AML-1 Phase 2 trial of triplet regimen design
Randomized portion of trial ~80 patients Tamibarotene + venetoclax + azacitidine Venetoclax + azacitidine randomization (1:1) Safety lead-in completed Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen (Tami/Ven/Aza) in newly diagnosed unfit AML patients with RARA overexpression Key Milestones In
Slide 11: Initial randomized SELECT-AML-1 data demonstrate 100% CR/CRi rate
Initial randomized SELECT-AML-1 Phase 2 data in newly diagnosed unfit AML patients with RARA overexpression demonstrate 100% CR/CRi rate CR/CRi Rate 70% CR/CRi Rate 100% CONTROL ARM: Ven/Aza TREATMENT ARM: Tami/Ven/Aza 22% CRi 78% CR CR Rate 78% CR/CRi Rate N=9 30% CR CR/CRi Rate N=10 CR Rate 30% Da
Slide 12: Hematologic safety profile shows no additive myelosuppression
Initial randomized SELECT-AML-1 Phase 2 data: Hematologic safety profile shows no additive myelosuppression when combining tamibarotene with Ven/Aza Febrile neutropenia Neutropenia Thrombocytopenia Leukopenia Anemia Hematologic AEs - All Causality Tami/Ven/Aza Safety Population, N=11; Ven/Aza Safety
Slide 13: Higher-Risk MDS (HR-MDS) is closely related to AML
1 Greenberg, Blood, 2012; 2Garcia, J et al., Leukemia Research, 2021; 3Elihu Estey, et al., Blood 2022 Higher-Risk MDS (HR-MDS) is closely related to AML Myelodysplastic syndrome (MDS) is also a cancer of the blood forming cells in the bone marrow HR-MDS often is a precursor to AML. More than half o
Slide 14: Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS
Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA overexpression Robustly designed, double-blind, placebo-controlled study 2:1 randomization Global study with over 120 sites recruiting in 13 countries FDA feedback supports: Focus on population with RARA overexpression C
Slide 15: Experienced leadership team and planning commercial launch
Experienced leadership team with proven capabilities and expertise in launching targeted oncology medicines Planning our distribution and sales infrastructure strategy for a launch in the U.S. Targeted patient populations will allow for a focused, specialized sales force Partnered with Qiagen to ens
Slide 16: Large market opportunities in frontline settings
Large market opportunities in frontline settings ~25,000 Newly Diagnosed Unfit AML patients in US and EU annually2 Building infrastructure to target synergistic patient populations underserved by existing options ~21,000 Newly Diagnosed HR-MDS patients in the US and EU annually1 ~$4.7B3 MYELODYSPLAS
Slide 17: Multiple near-term value-driving milestones and pre-launch activities underway
Multiple near-term value-driving milestones and pre-launch activities underway Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial Pivotal data from SELECT-MDS-1 Phase 3 trial Initial data from randomized SELECT-AML-1 trial Dec. 2023 Additional data from randomized SELECT-A
Slide 18: SYR2:S
SYR2:S
Syros Pharmaceuticals — JP Morgan Conference January 2024 on 6ix